Luminex Corporation announced it will unveil its new sample-to-answer system for infectious disease testing, ARIES at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). ARIES' scalable throughput, easy to use design, and networked data management software will deliver rapid results with a simple workflow.

The five assay launch menu targeted for the ARIES system will include: Flu A/B and RSV, HSV 1&2, Norovirus and Clostridium difficile (C. diff). Future menu items will be announced at a later date.

"ARIES will revolutionize molecular diagnostic testing with a system that integrates seamlessly into the laboratory," said Russell W. Bradley, senior vice president, corporate development and global marketing. "Enabling laboratories to produce faster results, and better manage their QC and compliance requirements can increase service levels to hospitals and doctors for improved patient care."

The 24th European Congress of Clinical Microbiology and Infectious Diseases is taking place in Barcelona, Spain, 10 – 13 May, 2014. ESCMID's yearly congress attracts around 10,000 participants.

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP open-architecture, multi-analyte platform and MultiCode real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers.